Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.

J Am Acad Dermatol

Dermatology Research and Education Foundation, Irvine, California. Electronic address:

Published: September 2020

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286262PMC
http://dx.doi.org/10.1016/j.jaad.2020.06.015DOI Listing

Publication Analysis

Top Keywords

assessing risk
4
risk dupilumab
4
dupilumab atopic
4
atopic dermatitis
4
dermatitis covid-19
4
covid-19 pandemic
4
assessing
1
dupilumab
1
atopic
1
dermatitis
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!